Business / Finance RSS Feed - Business / Finance

AMSBIO signs strategic marketing agreement with Luxcel Biosciences

AMSBIO has signed a strategic marketing agreement with Luxcel Biosciences to distribute their range of 96- and 384-well phosphorescence and fluorescence based assays. [More]
Amedica, Spinal Kinetics sign multi-year OEM agreement for silicon nitride spinal implants

Amedica, Spinal Kinetics sign multi-year OEM agreement for silicon nitride spinal implants

Amedica Corporation, a biomaterial company that has developed silicon nitride ceramics as a material platform to manufacture and commercialize orthopedic implants, is pleased to announce that it has entered into a multi-year original equipment manufacturer (OEM) agreement with Spinal Kinetics, a leading innovator of advanced spinal implant technologies. [More]
PGI net sales increase 72.3% to $498.0 million in third quarter 2014

PGI net sales increase 72.3% to $498.0 million in third quarter 2014

Polymer Group, Inc. reported results of operations for the third quarter ended September 27, 2014. [More]

Unilife submits 10-Q report for first quarter of FY 2015

Unilife Corporation ("Unilife" or "Company"), a developer and supplier of injectable drug delivery systems, today announced that it has submitted for filing its 10-Q report for the first quarter of Fiscal Year 2015 ending September 30, 2014. [More]
Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care announces new national contract under Comprehensive Hub Solutions Program

Linden Care LLC, a leading provider of comprehensive specialty pharmacy solutions to the pain management industry and a portfolio company of BelHealth Investment Partners, announced a new national contract under its Comprehensive Hub Solutions Program (the "Program"). [More]
MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement

MicroMatrices, Advanced Cell Diagnostics sign preferred partnership agreement

MicroMatrices, a service provider specialised in high resolution cell type-specific analysis to characterise toxicological responses in different cell types in tissue, today announced a preferred partnership agreement with Advanced Cell Diagnostics, Inc., a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools. [More]

Ranir acquires Oralys Dental

Building on its position as a global leader in private label consumer oral and personal health care products, Ranir, today announced it has acquired Oralys Dental, the leading provider of private label toothbrushes in France. [More]
Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014. [More]
Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash. [More]
Stradis Healthcare signs definitive agreement to acquire Medikmark

Stradis Healthcare signs definitive agreement to acquire Medikmark

Stradis Healthcare is pleased to announce that it has entered into a definitive acquisition agreement with Medikmark, a leading provider of healthcare kits based in Waukegan, IL, under which Stradis will acquire all shares of Medikmark. [More]
Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease. [More]
Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories reports net loss of $11.3 million for third quarter 2014

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the third quarter ended September 30, 2014, as well as recent business updates. [More]
Perrigo agrees to acquire Omega for $4.5 billion

Perrigo agrees to acquire Omega for $4.5 billion

Perrigo Company plc, a leading global provider of "Quality Affordable Healthcare Products," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for €3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for €2.48 billion and the assumption of €1.1 billion in debt. [More]
Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences announces acquisition of CorQuest Medical

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today that it has acquired U.S.-based CorQuest Medical Inc. CorQuest Medical specializes in the development of innovative devices and technologies for cardiac surgery. [More]
Gentiva Health Services reports revenues of $498.0 million for Q3 2014

Gentiva Health Services reports revenues of $498.0 million for Q3 2014

Gentiva Health Services, Inc., one of the largest providers of home health, hospice and community care services in the United States, today reported net revenues of $498.0 million, adjusted EBITDA of $48.5 million and adjusted income attributable to Gentiva shareholders per diluted share of $0.28. [More]
CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA, GenBiotech to jointly develop prolonged-release protein formulation for cartilage repair

CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed. [More]
Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Abide, Oxford partner to explore therapeutic potential of serine hydrolases

Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University Hospitals NHS Trust to explore the therapeutic potential of serine hydrolases, one of the largest enzyme classes with validated but under explored class of drug targets. [More]
AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors. [More]
Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals reports net loss of $20.9 million for third quarter of 2014

Rigel Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2014. [More]
Sigma-Aldrich acquires Cell Marque

Sigma-Aldrich acquires Cell Marque

Sigma-Aldrich Corporation, a leading Life Science and High Technology company, announced it has completed its acquisition of Rocklin, California based Cell Marque Corporation, an industry-leading provider of in vitro diagnostic (IVD) antibody reagents and kits. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed. [More]